GlassScriptPhysician profile
Lauren Ann Pankratz
NPI 1568675726
$16,491.10
in general payments reported to CMS, 2019-2025
54 companies · $3,218 in 2025
The $3,218 reported for 2025 was more than what 79% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,669 · 2020: $1,399 · 2021: $1,629 · 2022: $2,193 · 2023: $2,264 · 2024: $2,119 · 2025: $3,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,515 · Education: $73.98 · Travel and Lodging: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,514.58 |
| Education | $73.98 |
| Travel and Lodging | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $2,260.72 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $1,654.15 | 2019-2025 | Sogroya, Rybelsus, Ozempic |
| Abbvie INC. | $1,064.35 | 2019-2025 | |
| Insulet Corporation | $991.34 | 2019-2025 | Omnipod |
| Medtronic, INC. | $890.15 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Inceptiv |
| Lilly USA, LLC | $757.47 | 2019-2025 | Jardiance, Baqsimi, Mounjaro |
| Ascendis Pharma Endocrinology INC | $638.13 | 2022-2025 | Skytrofa |
| Abbott Laboratories | $579.26 | 2020-2025 | Freestyle Libre 3, Freestyle Libre |
| Tolmar, INC. | $528.41 | 2023-2025 | Fensolvi |
| Pfizer INC. | $499.48 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $412.91 | 2024-2025 | |
| Tolmar Pharmaceuticals, INC. | $403.79 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $376.58 | 2023-2025 | Triptodur, Triptodur, Vivimusta |
| Xeris Pharmaceuticals, INC. | $366.77 | 2020-2024 | Gvoke Hypopen |
| Mannkind Corporation | $363.18 | 2019-2025 | Afrezza |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eton Pharmaceuticals, INC. | $360.51 | 2023-2025 | Alkindi, Khindivi, Increlex |
| Neurocrine Biosciences, INC. | $340.31 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $299.95 | 2019-2023 | |
| Beta Bionics, INC. | $292.82 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $273.28 | 2025 | Twiist |
| Arbor Pharmaceuticals, INC. | $255.98 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $247.85 | 2019-2025 | Strensiq |
| Zealand Pharma US, INC. | $245.41 | 2021-2022 | |
| Soleno Therapeutics, INC. | $211.54 | 2025 | Vykat Xr |
| Dexcom, INC. | $201.04 | 2021-2025 | Dexcom G6 Transmitter |
| Ferring Pharmaceuticals INC. | $197.66 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $193.09 | 2022 | |
| Kyowa Kirin, INC. | $164.67 | 2023-2025 | Crysvita |
| Vistapharm, INC. | $148.06 | 2021 | |
| Medtronic Minimed, INC. | $135.53 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $123.04 | 2019-2021 | |
| Becton, Dickinson and Company | $99.96 | 2019-2022 | |
| Rhythm Pharmaceuticals, INC. | $82.70 | 2021-2023 | Imcivree |
| Ascensia Diabetes Care US INC. | $82.31 | 2023-2024 | |
| Sandoz INC. | $79.53 | 2019-2020 | |
| Organogenesis INC. | $79.46 | 2022-2023 | Puraply |
| Ibsa Pharma INC. | $73.13 | 2019-2025 | Licart, Flector, Tirosint |
| Amphastar Pharmaceuticals, INC. | $72.11 | 2024 | |
| Companion Medical, INC. | $71.47 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $60.67 | 2023-2024 | Isturisa, Signifor Lar |
| Astrazeneca Pharmaceuticals LP | $49.63 | 2019-2022 | |
| Endo USA, INC. | $34.52 | 2024-2025 | Supprelin |
| Merck Sharp & Dohme LLC | $24.94 | 2022 | |
| Corcept Therapeutics | $23.94 | 2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.09 | 2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $20.84 | 2025 | Shingrix, Arexvy |
| Amgen INC. | $19.80 | 2024 | Tepezza |
| Esperion Therapeutics, INC. | $19.33 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.15 | 2022 | |
| Valeritas, INC. | $17.29 | 2019 | |
| Averitas Pharma INC. | $17.16 | 2025 | Qutenza |
| Nevro Corp. | $16.49 | 2021 | |
| Antares Pharma, INC. | $15.70 | 2022 | |
| Radius Health, INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$345.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Pankratz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.